Rhinovirus Diagnostics Market Global Report 2026

The rhinovirus diagnostics market size has grown strongly in recent years. It will grow from $1.58 billion in 2025 to $1.71 billion in 2026 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to increasing prevalence of common cold and respiratory infections globally, rising adoption of molecular diagnostic techniques for viral detection, growth in hospital laboratory testing infrastructure, limitations of traditional culture-based virus detection methods, and increasing awareness of early infectious disease diagnosis.

The rhinovirus diagnostics market size is expected to see strong growth in the next few years. It will grow to $2.33 billion in 2030 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to rising demand for rapid point-of-care diagnostic solutions, integration of AI-based diagnostic interpretation tools, expansion of multiplex respiratory pathogen testing panels, increasing investment in infectious disease surveillance systems, and growth in personalized and precision medicine approaches for respiratory infections. Major trends in the forecast period include AI-assisted rapid respiratory pathogen detection and interpretation, expansion of multiplex PCR-based respiratory virus panels, growth of point-of-care rhinovirus diagnostic testing devices, integration of cloud-based infectious disease surveillance platforms, and advancements in high-sensitivity molecular diagnostic assays for early detection.

The rising prevalence of respiratory disorders is expected to propel the growth of the rhinovirus diagnostics market in the coming years. Respiratory disorders are conditions that affect the lungs and airways, making it difficult for individuals to breathe and properly exchange oxygen. The incidence of respiratory disorders is increasing mainly due to rising air pollution, which damages the lungs through continuous exposure to harmful pollutants and gradually weakens respiratory health over time. Rhinovirus diagnostics help in respiratory disorders by rapidly detecting rhinovirus infections, enabling timely and accurate treatment decisions that prevent complications and reduce the spread of respiratory illnesses. For instance, in December 2023, according to the National Center for Biotechnology Information, a US-based government agency, cases of Chronic Obstructive Pulmonary Disease (COPD) are expected to rise by 112 million, reaching a total of 592 million by 2050, accounting for 9.5% of the total eligible population. Therefore, the rising prevalence of respiratory disorders is driving the growth of the rhinovirus diagnostics market.

Major companies operating in the rhinovirus diagnostics market are focusing on developing innovative solutions such as rapid syndromic molecular diagnostics platforms to enable fast, accurate, and multiplex detection of respiratory pathogens for improved clinical decision-making. A rapid syndromic molecular diagnostics platform is a testing system that simultaneously identifies multiple pathogens from a single sample using molecular methods, enabling fast and accurate diagnosis of infections. For instance, in April 2023, bioMérieux S.A., a France-based biotechnology company, received U.S. Food and Drug Administration (FDA) 510(k) clearance for the BIOFIRE SPOTFIRE Respiratory (R) Panel Mini and announced plans to pursue CLIA-waiver status for the system. The panel is designed to rapidly detect multiple respiratory pathogens, including human rhinovirus/enterovirus, directly at the point of care. It supports faster diagnosis, streamlined workflow efficiency, and timely treatment decisions in outpatient and emergency care settings.

The rising healthcare expenditure is expected to propel the growth of the rhinovirus diagnostics market going forward. Healthcare expenditure refers to the total financial resources spent by individuals, organizations, or governments on preventing, treating, and managing health conditions. Healthcare expenditure is increasing due to advancements in medical technology, as new diagnostic tools, treatments, and innovative therapies often come with higher costs, leading to greater overall spending on healthcare. Higher healthcare expenditure supports rhinovirus diagnostics by enabling improved access to advanced testing technologies, strengthening diagnostic infrastructure, and increasing patient affordability and testing rates. For instance, in April 2025, according to the Office for National Statistics, a UK-based independent producer of official statistics, in 2024, the UK’s healthcare spending reached approximately $29.88 billion (£317 billion), reflecting a 6.5% nominal increase compared with 2023. Therefore, the rising healthcare expenditure is driving the growth of the rhinovirus diagnostics market.

Major companies operating in the rhinovirus diagnostics market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Becton Dickinson and Company, Quest Diagnostics Incorporated, Danaher Corporation (Cepheid), Hologic Inc., Bruker Corporation (ELITechGroup SAS), bioMérieux SA, Qiagen N.V., QuidelOrtho Corporation, DiaSorin S.p.A., Seegene Inc., ARUP Laboratories Inc., Sansure Biotech Inc., SRL Inc., R-Biopharm AG, CerTest Biotec S.L., SpeeDx Pty Ltd, GeneFirst Limited, Atila BioSystems Inc.

North America was the dominant region in the rhinovirus diagnostics market in 2025. Asia-Pacific is expected to be the rapidly expanding region in the forecast period. The regions covered in rhinovirus diagnostics report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the rhinovirus diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The rhinovirus diagnostics market consists of revenues earned by entities by providing services such as respiratory pathogen panel testing, rapid antigen testing, and sample collection services. The market value includes the value of related goods sold by the service provider or included within the service offering. The Rhinovirus diagnostics market also includes sales of PCR analyzers, real-time PCR machines, NGS sequencing instruments, and point-of-care testing devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The rhinovirus diagnostics market research report is one of a series of new reports that provides rhinovirus diagnostics market statistics, including rhinovirus diagnostics industry global market size, regional shares, competitors with a rhinovirus diagnostics market share, detailed rhinovirus diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the rhinovirus diagnostics industry. This rhinovirus diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.